Animal Gastroesophageal Reflux Disease Market Report: Market Size & Forecast 2026

The animal GERD market encompasses prescription and over-the-counter drugs, diagnostic tools, and adjunctive products used to manage gastroesophageal reflux in dogs, cats, horses, and other species. In 2025, the market is valued at approximately $1.98 billion and is projected to grow at a compound annual rate of around 8.5%. Long-term outlooks place the global market in the multi-billion-dollar range by the early 2030s, underscoring sustained momentum across both companion and production animal segments.

• •2025 market size: about $1.98 billion globally.
• •Forecast CAGR: roughly 8.5% through the early 2030s.
• •Scope includes pharmaceuticals, diagnostics, and supportive care for multiple animal species.

Rising companion animal populations and increased willingness among owners to pay for advanced veterinary care are the principal engines of market expansion. Greater awareness of gastrointestinal disorders in pets, combined with the trend toward pet humanization, is pushing demand for proton pump inhibitors, H2 blockers, antacids, and prokinetic agents tailored to veterinary use. At the same time, expanded access to veterinary specialists and improved diagnostic technologies such as endoscopy are enabling earlier and more accurate identification of reflux disease.

• •Rising pet ownership and willingness to spend on veterinary care.
• •Improved diagnostic capabilities, including endoscopic imaging.
• •Growing availability of species-appropriate acid-suppressive medications.

The market is commonly segmented by product, animal type (companion animals versus livestock), mode of administration, route of administration, and distribution channel, with veterinary hospitals and clinics representing the largest share of prescriptions. North America currently leads due to high pet ownership, advanced veterinary infrastructure, and strong spending per animal, while Europe follows closely. Asia-Pacific is emerging as the fastest-growing region, supported by expanding middle-class pet ownership, modernization of livestock practices, and increasing penetration of Western veterinary standards.

• •Companion animals represent the dominant animal segment.
• •North America holds the leading regional share; Asia-Pacific is the fastest-growing region.
• •Veterinary clinics and hospitals are the primary distribution channel.

What are the recent trends and outlook?

Key trends shaping the market include the development of novel gastrointestinal therapeutics, increased investment in animal health R&D, and growing emphasis on preventive veterinary care. Telemedicine and digital health platforms are making gastrointestinal consultations more accessible, while nutraceuticals and dietary management products are gaining traction as complementary therapies. Looking ahead, the market is expected to sustain strong growth through 2030 and beyond, driven by innovation, expanding veterinary services in emerging economies, and continued elevation of animal health standards globally.

• •Rising R&D in gastrointestinal therapeutics and species-specific drug delivery.
• •Telemedicine and digital vet platforms improving diagnosis of reflux conditions.
• •Preventive care, nutraceuticals, and dietary solutions emerging as complementary growth areas.